View more in
Cancer

Cilta-Cel Elicits Improved Outcomes in Relapsed/Refractory Myeloma vs Conventional Therapy

onclive.com
 2021-06-11

Cover picture for the articlePatients with relapsed/refractory multiple myeloma who were treated with ciltacabtagene autoleucel experienced improved outcomes over those who received a conventional therapy. Patients with relapsed/refractory multiple myeloma who were treated with ciltacabtagene autoleucel (JNJ-68284528; cilta-cel) experienced improved outcomes over those who received a conventional therapy, according to propensity score–matched analyses of the CARTITUDE-1 (NCT03548207) and MAMMOTH trials that were presented at the 2021 European Hematologic Association Congress.

www.onclive.com

Comments / 0

Comments / 0